US EditionCollegium to Participate in Upcoming Investor Conferences
Valneva's leadership will present key vaccine data and engage investors at U.S. and European conferences ahead of Pfizer's 2026 Phase 3 Lyme vaccine results.
- Valneva's management will present and meet with investors at conferences in Miami on March 10 and Amsterdam on April 15, 2026.
- Valneva will use the meetings to outline company strategy and key value drivers, emphasizing its strong track record and three proprietary travel vaccines.
- Access to the TD Cowen presentation will be provided via a live webcast with replay available in the investor section of Valneva's website at www.valneva.com.
- Investors should note the company's caution on forward-looking statements, warning that clinical, regulatory, manufacturing, competition, or intellectual property risks could affect results.
- Pfizer expects to report the VLA15 Phase 3 topline in the first half of 2026, positioning the result as a near-term catalyst discussed during investor meetings.
26 Articles
26 Articles
ivpressonline.com
Inhibrx Announces Participation in Upcoming Scientific Conference
SAN DIEGO, March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conference:
Hastings Tribune
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
Valneva to Participate in Upcoming Investor Conferences
Lyon (France), March 2, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Buhler will discuss the Company's key value drivers and upcoming catalysts, including the topline Phase 3 data readout for VLA15, the Company's Lyme disease vaccine candidate,…
Vistagen to Participate in Upcoming Investor Conferences
Coverage Details
Bias Distribution
- 77% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
